Allergies & Asthma

Patients with hereditary angioedema who were treated with an antisense oligonucleotide treatment, donidalorsen, experienced significantly fewer attacks than patients who received placebo, a phase II trial showed. Over 17 weeks, the mean number of investigator-confirmed angioedema attacks was 0.23 per month among the 14 patients treated with donidalorsen 80 mg every 4 weeks compared with
0 Comments
PHOENIX — Exacerbation-prone asthma patients who had high blood eosinophil counts or elevated fractional exhaled nitric oxide (FeNO) appeared to benefit from lebrikizumab, pooled data from two disappointing phase III trials suggested. In the post-hoc analysis of LAVOLTA I and LAVOLTA II, patients with at least one exacerbation in the prior year who had high
0 Comments
PHOENIX — Patients with severe, uncontrolled asthma experienced greater relief throughout the year when treated with the biologic tezepelumab (Tezspire) versus placebo, according to findings from the phase III NAVIGATOR study. Over 52 weeks, tezepelumab significantly reduced the annualized asthma exacerbation rate by 56% in the overall study population (P<0.001), and by 41% in those
0 Comments
PHOENIX — Adding mepolizumab (Nucala) to guideline-based care reduced flare-ups in disadvantaged kids with exacerbation-prone, eosinophilic asthma, the yearlong MUPPITS-2 trial showed. In the randomized study of nearly 300 kids living in urban parts of the U.S., the annualized exacerbation rate was 0.96 with mepolizumab versus 1.30 with placebo, representing a 27% relative decrease (rate
0 Comments
PHOENIX — Experts in lung diseases debated at the annual meeting of the American Academy of Allergy, Asthma & Immunology here whether at-home spirometry tests and devices, which are now available from multiple companies, should be elevated to prime-time use. The tests are good enough to allow patients to monitor their lung function at home
0 Comments
A drug-eluting contact lens containing an antihistamine for people with allergic eye itch won approval from the FDA, Johnson & Johnson Vision Care announced. The daily disposable etafilcon A drug-eluting contact lens with ketotifen (Acuvue Theravision with ketotifen) is the world’s first drug-eluting contact lens, the company said. It recently was approved in Japan and
0 Comments
PHOENIX — In some patients with eosinophilic asthma, dupilumab (Dupixent) offered the highest chance of better lung function, although the agent also carried the highest odds of serious adverse events (AEs), a researcher reported. In an indirect treatment comparison of dupilumab, mepolizumab (Nucala), and benralizumab (Fasenra), patients with eosinophil counts ≥300 cells/μL treated with dupilumab
0 Comments
Seasons change… Trees and flowers start budding to form colorful landscapes. Green-leafed trees change into a rainbow of fall colors. Those fall colors turn into a winter wonderland. Sounds pretty, right? What isn’t pretty — the misery that seasonal allergies often bring. Even though allergies cause problems year round, a number of environmental allergens “peak”
0 Comments
PHOENIX — Nearly three-fifths of patients with eosinophilic esophagitis (EoE) achieved remission after treatment with dupilumab (Dupixent), researchers reported. In a 6-month study, 58.8% of adults and adolescents treated with dupilumab achieved histological remission compared to 6.3% in the placebo group (P<0.0001), according to Marc Rothenberg, MD, PhD, of Cincinnati Children’s Hospital, in a pre-recorded
0 Comments
Black and Latinx patients who used an inhaled glucocorticoid as needed along with usual care had improved asthma outcomes, according to results from the PREPARE trial. In the study of patients with moderate-to-severe asthma, and compared to a control group that continued usual care only, the intervention group experienced a 15% decrease in risk of
0 Comments
Allergies are the 6th leading cause of chronic illness in the U.S. A majority of people avoid their allergens, manage their symptoms with temporary relief from over-the-counter (OTC) allergy medications, or just continue to suffer. Did you know there’s a personalized treatment to modify allergies and allergy-related chronic conditions beyond temporary relief? In this blog,
0 Comments
Patients who switched from a pressurized metered dose inhaler (pMDIs) to a dry powder inhaler (DPI) halved their carbon footprints while still maintaining good asthma control, a post-hoc analysis of the Salford Lung Study in Asthma showed. Including both maintenance and rescue asthma treatment, the annual per-patient carbon footprint equivalent (CO2e) dropped from a least
0 Comments